The US FDA’s novel agent approvals in 2024 travelled review paths that lasted from less than seven months to more than four years, the Pink Sheet US FDA Performance Tracker shows.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?